Health Catalyst, Inc. (NASDAQ:HCAT) Receives $12.77 Consensus Price Target from Analysts

Health Catalyst, Inc. (NASDAQ:HCATGet Free Report) has been assigned a consensus rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $12.77.

A number of equities analysts have recently weighed in on HCAT shares. Evercore ISI dropped their target price on Health Catalyst from $11.00 to $10.00 and set an “outperform” rating on the stock in a report on Friday, February 23rd. KeyCorp lowered their price target on shares of Health Catalyst from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Monday, February 26th. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a report on Tuesday, March 5th. Guggenheim upgraded Health Catalyst from a “neutral” rating to a “buy” rating and set a $14.00 target price on the stock in a research note on Friday, January 26th. Finally, JPMorgan Chase & Co. raised Health Catalyst from a “neutral” rating to an “overweight” rating and cut their price target for the stock from $14.00 to $11.00 in a research note on Wednesday, December 13th.

View Our Latest Stock Analysis on HCAT

Health Catalyst Price Performance

HCAT stock opened at $7.81 on Wednesday. Health Catalyst has a one year low of $6.60 and a one year high of $14.37. The firm has a 50-day moving average of $9.20 and a two-hundred day moving average of $8.99. The firm has a market capitalization of $457.35 million, a PE ratio of -3.76 and a beta of 1.30. The company has a current ratio of 4.42, a quick ratio of 4.42 and a debt-to-equity ratio of 0.62.

Health Catalyst (NASDAQ:HCATGet Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.06. The firm had revenue of $75.08 million for the quarter, compared to analysts’ expectations of $73.67 million. Health Catalyst had a negative net margin of 39.92% and a negative return on equity of 12.19%. On average, analysts forecast that Health Catalyst will post -0.47 earnings per share for the current year.

Insider Transactions at Health Catalyst

In other news, insider Linda Llewelyn sold 3,163 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $10.83, for a total transaction of $34,255.29. Following the transaction, the insider now owns 68,048 shares in the company, valued at approximately $736,959.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 2.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Health Catalyst

A number of institutional investors and hedge funds have recently modified their holdings of the company. Fairfield Bush & CO. bought a new position in shares of Health Catalyst during the 1st quarter worth about $25,000. Point72 Hong Kong Ltd bought a new position in Health Catalyst during the first quarter worth about $33,000. Macquarie Group Ltd. acquired a new stake in Health Catalyst during the second quarter valued at approximately $26,000. Tower Research Capital LLC TRC grew its stake in shares of Health Catalyst by 165.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,118 shares of the company’s stock valued at $32,000 after purchasing an additional 1,942 shares during the period. Finally, Advisor Group Holdings Inc. raised its holdings in shares of Health Catalyst by 86.3% in the 1st quarter. Advisor Group Holdings Inc. now owns 5,324 shares of the company’s stock worth $137,000 after buying an additional 2,467 shares in the last quarter. 86.63% of the stock is currently owned by institutional investors.

About Health Catalyst

(Get Free Report

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.

Featured Articles

Analyst Recommendations for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.